Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1978 Feb;19(2):391–394. doi: 10.1128/iai.19.2.391-394.1978

Immunity to Mycobacterium leprae infections induced in mice by BCG vaccination at different times before or after challenge.

C C Shepard, L L Walker, R M Van Landingham
PMCID: PMC414095  PMID: 344208

Abstract

Viable suspensions of BCG, an attenuated strain of Mycobacterium bovis, have been previously shown to immunize mice against infections with M. leprae. Usually, the mice have been vaccinated about 1 month before challenge. Experiments have now been carried out with single intradermal injections of BCG given before or after the M. leprae challenge. Approximately equal immunizing effect was seen in one experiment when the BCG was given at -168, -119, -70, and -28 days relative to challenge. Approximately equal protection was observed in another experiment when the vaccine was given at -28, +28, and +56 days. In the latter experiment, however, vaccine given at +91 days appeared to be somewhat less effective. Enlargement of the lymph nodes regional to the intradermal vaccine site persisted for at least the duration of the experiment, approximately 400 days. Thus, antigenic stimulation appears to have continued throughout the period of observation.

Full text

PDF
391

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bechelli L. M., Garbajosa G., Uemura K., Engler V., Martínez Domínguez V., Paredes L., Sundaresan T., Koch G., Matejka M. BCG vaccination of children against leprosy. Preliminary findings of the WHO-controlled trial in Burma. Bull World Health Organ. 1970;42(2):235–281. [PMC free article] [PubMed] [Google Scholar]
  2. Brown J. A., Stone M. M., Sutherland I. Trial of BCG vaccination against leprosy in Uganda. Lepr Rev. 1969 Jan;40(1):3–7. doi: 10.5935/0305-7518.19690003. [DOI] [PubMed] [Google Scholar]
  3. Bucana C., Hanna M. G., Jr Immunoelectronmicroscopic analysis of surface antigens common to Mycobacterium bovis (BCG) and tumor cells. J Natl Cancer Inst. 1974 Nov;53(5):1313–1323. doi: 10.1093/jnci/53.5.1313. [DOI] [PubMed] [Google Scholar]
  4. Minden P., McClatchy J. K., Wainberg M., Weiss D. W. Shared antigens between Mycobacterium bovis (BCG) and neoplastic cells. J Natl Cancer Inst. 1974 Nov;53(5):1325–1331. doi: 10.1093/jnci/53.5.1325. [DOI] [PubMed] [Google Scholar]
  5. Paul R. C., Stanford J. L., Carswell J. W. Multiple skin testing in leprosy. J Hyg (Lond) 1975 Aug;75(1):57–68. doi: 10.1017/s0022172400047069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ranne G. H., Smith M. E., Ford W. L. Lymphocyte migration into cell-mediated immune lesions is inhibited by trypsin. Nature. 1977 Jun 9;267(5611):520–522. doi: 10.1038/267520a0. [DOI] [PubMed] [Google Scholar]
  7. SHEPARD C. C. VACCINATION AGAINST EXPERIMENTAL INFECTION WITH MYCOBACTERIUM LEPRAE. Am J Epidemiol. 1965 Mar;81:150–163. doi: 10.1093/oxfordjournals.aje.a120504. [DOI] [PubMed] [Google Scholar]
  8. Shepard C. C., McRae D. H. A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis. 1968 Jan-Mar;36(1):78–82. [PubMed] [Google Scholar]
  9. Shepard C. C. Vaccination against human leprosy bacillus infections of mice: protection by BCG given during the incubation period. J Immunol. 1966 Feb;96(2):279–283. [PubMed] [Google Scholar]
  10. Shepard C. C., Van Landingham R., Walker L. L. Immunity to Mycobacterium leprae infections in mice stimulated by M. leprae, BCG, and graft-versus-host reactions. Infect Immun. 1976 Oct;14(4):919–928. doi: 10.1128/iai.14.4.919-928.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES